PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
799.80%
Cash & equivalents growing 799.80% while AXSM's declined -3.36%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
799.80%
Below half of AXSM's -3.36%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
700.88%
Below half of AXSM's -3.44%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.67%
0.75-0.9x AXSM's -11.87%. Bill Ackman questions if competitor invests more heavily in future capacity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.93%
≥ 1.5x AXSM's -4.38%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Below half of AXSM's -3.44%. Michael Burry sees a potential red flag for stagnation or capital shortage.
1.26%
Less than half of AXSM's -23.20%. David Dodd sees a more disciplined AP approach or lower volume.
-42.54%
Less than half of AXSM's 43.32%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
5.04%
Below half of AXSM's -28.42%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
-1.15%
Less than half of AXSM's -11.87%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
1.25-1.5x AXSM's -11.58%. Martin Whitman is wary of heavier future burdens.
No Data
No Data available this quarter, please select a different quarter.
-2.99%
Less than half of AXSM's -11.76%. David Dodd sees far fewer liability expansions relative to competitor.
-92.57%
Less than half of AXSM's 0.51%. David Dodd sees fewer share issuances vs. competitor.
-2.16%
Below half AXSM's -8.80%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1581.26%
≥ 1.5x AXSM's 174.02%. David Dodd sees stronger capital base growth than competitor.
569.03%
≥ 1.5x AXSM's 214.55%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Less than half of AXSM's 0.89%. David Dodd sees less overall debt expansion vs. competitor.
-1028.99%
Less than half of AXSM's 3.84%. David Dodd sees better deleveraging or stronger cash buildup than competitor.